Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 46 studies | 42% ± 16% | |
| endothelial cell of lymphatic vessel | 25 studies | 48% ± 16% | |
| pericyte | 21 studies | 34% ± 14% | |
| oligodendrocyte | 16 studies | 58% ± 16% | |
| astrocyte | 15 studies | 40% ± 20% | |
| fibroblast | 15 studies | 34% ± 18% | |
| smooth muscle cell | 14 studies | 29% ± 9% | |
| endothelial cell of artery | 13 studies | 36% ± 15% | |
| microglial cell | 13 studies | 37% ± 12% | |
| endothelial cell of vascular tree | 11 studies | 35% ± 16% | |
| basal cell | 11 studies | 38% ± 17% | |
| type II pneumocyte | 10 studies | 59% ± 20% | |
| epithelial cell | 10 studies | 40% ± 20% | |
| ciliated cell | 10 studies | 29% ± 12% | |
| capillary endothelial cell | 9 studies | 42% ± 13% | |
| macrophage | 9 studies | 26% ± 8% | |
| vein endothelial cell | 9 studies | 39% ± 14% | |
| GABAergic neuron | 8 studies | 41% ± 14% | |
| oligodendrocyte precursor cell | 8 studies | 28% ± 12% | |
| type I pneumocyte | 7 studies | 38% ± 9% | |
| club cell | 7 studies | 49% ± 16% | |
| amacrine cell | 7 studies | 45% ± 15% | |
| respiratory goblet cell | 6 studies | 44% ± 19% | |
| interneuron | 6 studies | 41% ± 16% | |
| retinal ganglion cell | 6 studies | 40% ± 18% | |
| retinal cone cell | 6 studies | 46% ± 16% | |
| Mueller cell | 6 studies | 24% ± 7% | |
| glutamatergic neuron | 5 studies | 33% ± 11% | |
| OFF-bipolar cell | 5 studies | 31% ± 11% | |
| retina horizontal cell | 5 studies | 64% ± 13% | |
| cardiac muscle cell | 5 studies | 60% ± 11% | |
| neuron | 5 studies | 42% ± 16% | |
| ionocyte | 4 studies | 25% ± 6% | |
| secretory cell | 4 studies | 31% ± 13% | |
| granule cell | 4 studies | 35% ± 17% | |
| ON-bipolar cell | 4 studies | 35% ± 13% | |
| glycinergic amacrine cell | 4 studies | 41% ± 13% | |
| retinal pigment epithelial cell | 4 studies | 41% ± 13% | |
| adipocyte | 4 studies | 24% ± 7% | |
| muscle cell | 4 studies | 40% ± 27% | |
| goblet cell | 4 studies | 34% ± 23% | |
| squamous epithelial cell | 3 studies | 49% ± 20% | |
| pancreatic A cell | 3 studies | 25% ± 8% | |
| glomerular endothelial cell | 3 studies | 38% ± 9% | |
| GABAergic interneuron | 3 studies | 27% ± 8% | |
| glial cell | 3 studies | 28% ± 11% | |
| retinal bipolar neuron | 3 studies | 39% ± 9% | |
| endocardial cell | 3 studies | 51% ± 3% | |
| mesothelial cell | 3 studies | 27% ± 6% | |
| lymphocyte | 3 studies | 30% ± 17% | |
| GABAergic amacrine cell | 3 studies | 37% ± 13% | |
| retinal rod cell | 3 studies | 29% ± 3% | |
| rod bipolar cell | 3 studies | 33% ± 6% | |
| hepatocyte | 3 studies | 66% ± 16% | |
| ependymal cell | 3 studies | 40% ± 20% | |
| myeloid cell | 3 studies | 21% ± 0% | |
| myofibroblast cell | 3 studies | 31% ± 11% | |
| renal principal cell | 3 studies | 25% ± 7% | |
| mucus secreting cell | 3 studies | 44% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 5402.08 | 1445 / 1445 | 98% | 37.47 | 180 / 183 |
| pancreas | 100% | 10651.07 | 328 / 328 | 98% | 27.81 | 175 / 178 |
| lung | 99% | 6146.30 | 574 / 578 | 99% | 35.89 | 1138 / 1155 |
| brain | 100% | 7204.60 | 2639 / 2642 | 98% | 21.81 | 690 / 705 |
| prostate | 100% | 5992.45 | 245 / 245 | 96% | 23.14 | 483 / 502 |
| stomach | 100% | 6309.52 | 359 / 359 | 95% | 27.96 | 272 / 286 |
| thymus | 100% | 5602.89 | 652 / 653 | 95% | 31.48 | 575 / 605 |
| breast | 100% | 9081.31 | 459 / 459 | 94% | 28.40 | 1053 / 1118 |
| intestine | 100% | 5070.24 | 965 / 966 | 94% | 20.83 | 495 / 527 |
| bladder | 100% | 5495.10 | 21 / 21 | 87% | 16.24 | 438 / 504 |
| uterus | 100% | 6009.54 | 170 / 170 | 87% | 17.58 | 398 / 459 |
| liver | 100% | 5087.42 | 226 / 226 | 83% | 15.70 | 337 / 406 |
| adrenal gland | 100% | 7653.81 | 258 / 258 | 83% | 15.11 | 190 / 230 |
| kidney | 97% | 2585.39 | 86 / 89 | 78% | 14.48 | 703 / 901 |
| ovary | 100% | 8678.12 | 180 / 180 | 57% | 5.34 | 244 / 430 |
| skin | 72% | 3773.98 | 1308 / 1809 | 84% | 19.40 | 397 / 472 |
| adipose | 100% | 8236.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 100% | 8840.30 | 803 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 6189.19 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 7737.05 | 856 / 861 | 0% | 0 | 0 / 0 |
| spleen | 97% | 2391.42 | 233 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 26.41 | 42 / 45 |
| eye | 0% | 0 | 0 / 0 | 39% | 5.13 | 31 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.19 | 1 / 29 |
| peripheral blood | 0% | 5.25 | 3 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0010758 | Biological process | regulation of macrophage chemotaxis |
| GO_0005730 | Cellular component | nucleolus |
| GO_0005813 | Cellular component | centrosome |
| GO_0005615 | Cellular component | extracellular space |
| GO_0015630 | Cellular component | microtubule cytoskeleton |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005874 | Cellular component | microtubule |
| GO_0005819 | Cellular component | spindle |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0005634 | Cellular component | nucleus |
| GO_0008017 | Molecular function | microtubule binding |
| Gene name | MTUS1 |
| Protein name | Microtubule associated scaffold protein 1 Microtubule-associated tumor suppressor 1 (AT2 receptor-binding protein) (Angiotensin-II type 2 receptor-interacting protein) (Mitochondrial tumor suppressor 1) |
| Synonyms | GK1 ATBP ATIP KIAA1288 MTSG1 |
| Description | FUNCTION: Cooperates with AGTR2 to inhibit ERK2 activation and cell proliferation. May be required for AGTR2 cell surface expression. Together with PTPN6, induces UBE2V2 expression upon angiotensin-II stimulation. Isoform 1 inhibits breast cancer cell proliferation, delays the progression of mitosis by prolonging metaphase and reduces tumor growth. . |
| Accessions | ENST00000262102.10 [Q9ULD2-1] ENST00000693296.1 [Q9ULD2-1] H0YC63 ENST00000381869.5 [Q9ULD2-2] ENST00000634613.1 [Q9ULD2-4] Q9ULD2 ENST00000297488.10 [Q9ULD2-3] ENST00000381861.7 [Q9ULD2-6] ENST00000519263.5 [Q9ULD2-2] ENST00000544260.3 [Q9ULD2-7] A0A0U1RQI2 ENST00000520196.5 ENST00000519066.5 |